Full access
Professional News
Published Online: 16 December 2005

Experimental Drug Shows Promise for Smoking Cessation

Eve BenderAuthors Info & Affiliations
Publication: Psychiatric News
Volume 40, Number 24
https://doi.org/10.1176/pn.40.24.0008b
PDF/EPUB
Smokers taking an experimental drug in late-stage clinical trials were twice as likely to quit as those who took bupropion, the old standby for smoking-cessation treatment, according to findings presented at an American Heart Association meeting in Dallas in November.
These findings were also announced in a press release from Pfizer Inc. last month. The company makes the new drug.
In two double-blind, placebo-controlled studies conducted in the United States, about 2,000 smokers received the experimental drug, varenicline, another group received bupropion (marketed under the brand name Zyban), and a third group received placebo for a duration of 12 weeks.
Varenicline, which is manufactured by Pfizer, is a selective nicotinic acetylcholine receptor partial agonist and is designed to bind to the same receptor sites as nicotine.
In addition to relieving the craving and withdrawal symptoms associated with quitting smoking, the drug blocks the rewarding effects of nicotine.
In both studies, 44 percent of those treated with varenicline quit smoking by the end of the 12-week treatment period, while just 30 percent of those taking bupropion did. Of those taking placebo, 18 percent quit.
According to the data, the odds of quitting smoking for subjects taking varenicline were about two times higher than for those taking bupropion and four times higher than for those on placebo.
After a year, patients who received varenicline were significantly more likely to have abstained from smoking than were those who took bupropion. (The odds ratio for varenicline vs. bupropion was about 1.5).
In a third trial conducted at study sites in the United States and Europe, researchers randomized 1,206 subjects who had quit smoking after 12 weeks of varenicline treatment to another 12 weeks of either placebo or continuing treatment with varenicline.
Researchers followed the subjects for 28 weeks and found that 71 percent of those who received the additional treatment with varenicline remained abstinent after six months, compared with 50 percent who received placebo.
According to Pfizer's press release, varenicline was well tolerated in all three trials, and the side effects cited most frequently were nausea, headache, trouble sleeping, and abnormal dreams.
Pfizer submitted a new drug application for varenicline to the Food and Drug Administration in November, and if it is approved the drug will be marketed under the brand name Champix.
More information about varenicline is posted at<www.pfizer.com>.▪

Information & Authors

Information

Published In

Go to Psychiatric News
Psychiatric News
Volume 40 • Number 24 • December 16, 2005
Pages: 8

History

Published online: 16 December 2005
Published in print: December 16, 2005

Notes

An experimental drug that targets smokers outperforms the only oral prescription medicine marketed for smoking cessation, according to findings from late-stage clinical trials.

Authors

Details

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share

×

As described within the American Psychiatric Association (APA)'s Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences. Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.